Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | 37.1x - 41.0x | 39.0x |
| Selected Fwd P/E Multiple | 18.7x - 20.7x | 19.7x |
| Fair Value | ﷼42.19 - ﷼46.63 | ﷼44.41 |
| Upside | -10.0% - -0.6% | -5.3% |
| Benchmarks | - | Full Ticker |
| Mouwasat Medical Services Company | 400,200.0% | SASE:4002 |
| Al Hammadi Holding Company | 400,700.0% | SASE:4007 |
| Almoosa Health Company | 401,800.0% | SASE:4018 |
| Dr. Sulaiman Al Habib Medical Services Group Company | 401,300.0% | SASE:4013 |
| Middle East Healthcare Company | 400,900.0% | SASE:4009 |
| Dr. Soliman Abdel Kader Fakeeh Hospital Company | 401,700.0% | SASE:4017 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| 4002 | 4007 | 4018 | 4013 | 4009 | 4017 | |||
| SASE:4002 | SASE:4007 | SASE:4018 | SASE:4013 | SASE:4009 | SASE:4017 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 8.9% | 29.5% | NM- | 21.6% | 23.6% | -0.9% | ||
| 3Y CAGR | 3.8% | 50.8% | 14.8% | 18.9% | 154.0% | -4.9% | ||
| Latest Twelve Months | -1.8% | 11.7% | -3.8% | 13.2% | 1555.1% | 2.8% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 26.5% | 19.5% | 9.1% | 19.8% | 4.4% | 11.9% | ||
| Prior Fiscal Year | 24.3% | 25.8% | 10.0% | 21.5% | 0.6% | 12.0% | ||
| Latest Fiscal Year | 22.4% | 29.4% | 7.9% | 20.7% | 9.8% | 10.3% | ||
| Latest Twelve Months | 22.4% | 29.4% | 7.9% | 20.7% | 9.8% | 10.3% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 15.3x | 16.1x | 30.0x | 39.5x | 13.1x | 25.0x | ||
| Price / LTM Sales | 4.9x | 5.5x | 5.3x | 9.0x | 2.0x | 3.9x | ||
| LTM P/E Ratio | 22.0x | 18.9x | 67.7x | 43.8x | 20.5x | 37.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | 18.9x | 22.0x | 67.7x | |||||
| Historical LTM P/E Ratio | 37.5x | 37.5x | 37.5x | |||||
| Selected P/E Multiple | 37.1x | 39.0x | 41.0x | |||||
| (x) LTM Net Income | 288 | 288 | 288 | |||||
| (=) Equity Value | 10,658 | 11,219 | 11,780 | |||||
| (/) Shares Outstanding | 230.0 | 230.0 | 230.0 | |||||
| Implied Value Range | 46.34 | 48.78 | 51.22 | |||||
| FX Rate: SAR/SAR | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 46.34 | 48.78 | 51.22 | 46.90 | ||||
| Upside / (Downside) | -1.2% | 4.0% | 9.2% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 4002 | 4007 | 4018 | 4013 | 4009 | 4017 | |
| Value of Common Equity | 14,180 | 6,392 | 6,389 | 101,360 | 5,771 | 10,787 | |
| (/) Shares Outstanding | 200.0 | 160.0 | 44.3 | 350.0 | 92.0 | 230.0 | |
| Implied Stock Price | 70.90 | 39.95 | 144.20 | 289.60 | 62.70 | 46.90 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 70.90 | 39.95 | 144.20 | 289.60 | 62.70 | 46.90 | |
| Trading Currency | SAR | SAR | SAR | SAR | SAR | SAR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |